Incyclix Bio is a development-stage pharmaceutical company developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. The team’s unique insights about the biology and structure of CDKs will facilitate the rapid discovery and development of a novel, potent, and selective CDK2 inhibitor to treat patients whose tumors are insensitive to CDK4/6 inhibition.
Sapience Therapeutics is a clinical stage biotechnology company focused on developing its lead compound, ST101, which is a peptide inhibitor of C/EBPbeta. It has FDA Fast Track designation for advanced cutaneous melanoma and GBM. The pipeline is full of other compounds, including a beta-catenin antagonist.